<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958746</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-308</org_study_id>
    <nct_id>NCT04958746</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial Evaluating the Efficacy and Safety of Ciprofol Injection for the Induction of Sedation/Anesthesia in Subjects Undergoing Gynecological Outpatient Surgeries</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Propofol Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of Ciprofol Injection for the Induction of Sedation/Anesthesia in Subjects Undergoing Gynecological Outpatient Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, double-blind, Propofol parallel-controlled phase&#xD;
      III clinical study, with the primary objective of evaluating the efficacy of Ciprofol vs.&#xD;
      Propofol for the induction of sedation/anesthesia in subjects undergoing gynecological&#xD;
      outpatient surgeries and secondary objective of evaluating the safety of Ciprofol in subjects&#xD;
      undergoing gynecological outpatient surgeries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of anesthesia</measure>
    <time_frame>Day 1</time_frame>
    <description>The proportion of subjects successfully anesthetized in all subjects of the group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to successful sedation/anesthetic induction</measure>
    <time_frame>Day 1</time_frame>
    <description>Time from the initial administration of the investigational drug to the first time when MOAA/S is ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fully awake</measure>
    <time_frame>Day 1</time_frame>
    <description>Time from the last administration of the investigational drug to the first of 3 consecutive MOAA/S scores = 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Gynecological Outpatient Surgery</condition>
  <arm_group>
    <arm_group_label>Ciprofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofol group：0.4/0.2mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Propofol group：2.0/1.0mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofol</intervention_name>
    <description>intravenous bolus</description>
    <arm_group_label>Ciprofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>intravenous bolus</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient needing gynecological outpatient surgery under general anesthesia without&#xD;
             endotracheal intubation;&#xD;
&#xD;
          2. Female, aged between 18-65 (inclusive);&#xD;
&#xD;
          3. American Society of Anesthesiologists (ASA) Class I- II&#xD;
&#xD;
          4. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2;&#xD;
&#xD;
          5. Vital signs during the screening period meet the following criteria:&#xD;
&#xD;
               1. Respiratory rate ≥ 10 and ≤ 24 breaths/min;&#xD;
&#xD;
               2. Pulse oxygen saturation (SpO2) ≥ 95% when inhaling;&#xD;
&#xD;
               3. Systolic blood pressure (SBP) ≥ 85 mmHg and ≤ 140 mmHg;&#xD;
&#xD;
               4. Diastolic blood pressure (DBP) ≥ 50 mmHg and ≤ 90 mmHg;&#xD;
&#xD;
               5. Heart rate ≥ 50 beats/min and ≤ 100 beats/min. (Note: For heart rate, the heart&#xD;
                  rate results of 12-ECG examination are used as the basis for judging whether the&#xD;
                  inclusion criteria are met.)&#xD;
&#xD;
          6. Capable of understanding the procedure and method of this study, willing to sign an&#xD;
             informed consent form and to complete this study in strict accordance with the study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with contraindications to deep sedation/general anesthesia or a history of&#xD;
             past sedation/anesthesia accidents;&#xD;
&#xD;
          2. Known sensitivity to Propofol Injection, Ciprofol Injection, the excipients in the&#xD;
             investigational drugs (soybean oil, glycerin, triglyceride, egg lecithin, purified&#xD;
             lecithin, sodium oleate, sodium hydroxide and disodium edetate), and opioids or any&#xD;
             ingredient of opioids; contraindications to Propofol;&#xD;
&#xD;
          3. Patients with positive urine HCG or blood HCG (except abortion, dilatation and&#xD;
             curettage, other outpatient surgeries for termination of pregnancy);&#xD;
&#xD;
          4. Patients having the following medical history or evidence prior to screening, which&#xD;
             may increase sedation/anesthesia risk:&#xD;
&#xD;
               1. History of cardiovascular diseases: Uncontrolled hypertension or SBP &gt; 140 mmHg&#xD;
                  and/or DBP &gt; 90 mmHg despite antihypertensive treatment, severe arrhythmia, heart&#xD;
                  failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6&#xD;
                  months prior to screening, history of tachycardia/bradycardia requiring&#xD;
                  medication, third-degree atrioventricular block or QTcF interval ≥ 450 ms&#xD;
                  (Fridericia's correction formula) during screening;&#xD;
&#xD;
               2. Respiratory system disorders: Respiratory insufficiency, history of obstructive&#xD;
                  pulmonary disease, history of bronchospasm requiring treatment within 3 months&#xD;
                  prior to screening, acute respiratory tract infection with any one of the obvious&#xD;
                  symptoms such as fever, wheezing, or productive cough within 1 week prior to&#xD;
                  screening;&#xD;
&#xD;
               3. History of neurological and mental disorders: history of craniocerebral injury,&#xD;
                  convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, or&#xD;
                  cerebrovascular accident; history of schizophrenia, mania, chronic use of&#xD;
                  antipsychotics, cognitive impairment, etc.;&#xD;
&#xD;
               4. History of gastrointestinal diseases: history of gastrointestinal retention,&#xD;
                  active hemorrhage, gastroesophageal reflux or obstruction, etc. which may cause&#xD;
                  reflux and aspiration, as per the judgment of the investigator;&#xD;
&#xD;
               5. History of uncontrolled and clinically significant diseases in such as liver,&#xD;
                  kidney, blood system, nervous system, or metabolic system judged by the&#xD;
                  investigator to be unsuitable for this trial;&#xD;
&#xD;
               6. History of alcohol abuse within 3 months prior to screening, abuse defined as&#xD;
                  average of &gt; 2 units of alcohol per day (1 unit = 360 mL of beer or 45 mL of&#xD;
                  liquor with 40% alcohol or 150 mL of wine);&#xD;
&#xD;
               7. History of drug abuse within 3 months prior to screening;&#xD;
&#xD;
               8. Serious infection, trauma, or major surgery within 4 weeks prior to screening.&#xD;
&#xD;
          5. Patients with the following airway management risks at screening:&#xD;
&#xD;
               1. Asthma history, and stridor;&#xD;
&#xD;
               2. Sleep apnea syndrome;&#xD;
&#xD;
               3. History or family history of malignant hyperthermia;&#xD;
&#xD;
               4. History of intubation failure;&#xD;
&#xD;
               5. Judged by the investigator to have difficult airway or judged as difficult&#xD;
                  tracheal intubation (modified Mallampati score III or IV).&#xD;
&#xD;
          6. Receiving any one of the following medications or treatments at screening:&#xD;
&#xD;
               1. Participated in other clinical trials of drugs within 1 month prior to screening;&#xD;
&#xD;
               2. Used Propofol, other general sedatives/anesthetics, and/or opioid analgesics or&#xD;
                  compounds containing opioid analgesics within 3 days prior to screening.&#xD;
&#xD;
          7. Patient whose laboratory parameters measured at screening meet any of the following&#xD;
             criteria and are verified through reexamination:&#xD;
&#xD;
               1. Neutrophil count &lt; 1.5 × 109/L;&#xD;
&#xD;
               2. Platelet count &lt; 80 × 109/L;&#xD;
&#xD;
               3. Hemoglobin &lt; 90 g/L;&#xD;
&#xD;
               4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3.0 × upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               5. Total bilirubin &gt; 2 × ULN;&#xD;
&#xD;
               6. Serum creatinine &gt; 1.5 × ULN.&#xD;
&#xD;
          8. Breastfeeding females; women of child-bearing potential who are unwilling to use&#xD;
             contraception during the trial; or subjects who are planning pregnancy within 1 month&#xD;
             after completion of the trial.&#xD;
&#xD;
          9. Subject judged by the investigator to have any other factors unsuitable for&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

